CADTH Canadian Drug Expert Committee final recommendation: Emtricitabine / tenofovir alafenamide (Descovy -- Gilead Sciences Canada, Inc.) indication : HIV-1 infection
The CADTH Canadian Drug Expert Committee (CDEC) recommends that emtricitabine/tenofovir alafenamide (FTC/TAF) be reimbursed for use in combination with other antiretrovirals (ARVs) (such as non-nucleoside reverse transcriptase inhibitors [NNRTIs] or protease inhibitors) for the treatment of human im...
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, August 24, 2016
|
Series: | Common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that emtricitabine/tenofovir alafenamide (FTC/TAF) be reimbursed for use in combination with other antiretrovirals (ARVs) (such as non-nucleoside reverse transcriptase inhibitors [NNRTIs] or protease inhibitors) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients aged 12 years and older |
---|---|
Physical Description: | 1 PDF file (5 pages) |